Longevity SciNeuro lands $53m to address the underlying biology of neurodegenerationBy adminDecember 4, 20250 With programs targeting Alzheimer’s and Parkinson’s, company targets several major drivers of neurodegenerative disease. US biotech SciNeuro Pharmaceuticals has secured…